Physician profile
David Berger
NPI 1881683944
$80,954.54
in general payments reported to CMS, 2019-2025
26 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $14K · 2021: $1,351 · 2022: $168 · 2023: $266 · 2024: $275 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40,226.30 | 2019-2021 | |
| Novo Nordisk INC | $20,113.93 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $15,712.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $2,591.89 | 2019-2022 | |
| Abbvie INC. | $280.18 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $276.34 | 2022-2023 | |
| Amgen INC. | $266.14 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $235.01 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $201.41 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $187.39 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $155.13 | 2024 | Isturisa |
| Horizon Therapeutics Plc | $123.43 | 2021 | |
| Ascendis Pharma Endocrinology INC | $107.71 | 2025 | Yorvipath |
| Janssen Pharmaceuticals, INC | $102.30 | 2019-2020 | |
| Insulet Corporation | $48.62 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amerisourcebergen Drug Corporation | $48.25 | 2019 | |
| Corcept Therapeutics | $41.61 | 2019-2020 | |
| Radius Health, INC. | $38.81 | 2019-2020 | |
| Becton, Dickinson and Company | $36.53 | 2020 | |
| Acerus Pharmaceuticals Corporation | $29.81 | 2020 | |
| Medtronic Minimed, INC. | $29.71 | 2020 | |
| Mannkind Corporation | $29.36 | 2019-2020 | |
| Ibsa Pharma INC. | $22.95 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.06 | 2019 | |
| Gilead Sciences, INC. | $17.00 | 2022 | |
| Antares Pharma, INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.